Sleep Aid (insomnia) Patents (Class 514/923)
  • Patent number: 8926991
    Abstract: The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: January 6, 2015
    Assignee: Botulinum Toxin Research Associates, Inc.
    Inventor: Gary E. Borodic
  • Patent number: 8691275
    Abstract: This disclosure relates to controlled-release melatonin compositions and related methods. In one embodiment, a controlled-release medicament composition comprises melatonin dispersed in a controlled melatonin release portion comprising a polymer matrix, the polymer matrix adapted to encapsulate the melatonin in a melatonin solubility enhancing pH environment and to maintain the melatonin solubility enhancing pH environment when the composition is located in a melatonin solubility diminishing pH environment for allowing an effective amount of melatonin to be released into the melatonin solubility diminishing pH environment.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: April 8, 2014
    Assignee: ZX Pharma, LLC
    Inventors: Syed M. Shah, Daniel Hassan
  • Patent number: 8252809
    Abstract: The present invention provides compositions for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: August 28, 2012
    Assignee: Transcept Pharmaceuticals, Inc.
    Inventor: Nikhilesh N. Singh
  • Patent number: 8242131
    Abstract: The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: August 14, 2012
    Assignee: Transcept Pharmaceuticals, Inc.
    Inventors: Nikhilesh Singh, Sathasivan Indiran Pather
  • Patent number: 8197860
    Abstract: The present application relates to a method for enhancing absorption of a nutrient in a subject in need thereof with an effective amount of an isolated astragaloside compound.
    Type: Grant
    Filed: April 15, 2009
    Date of Patent: June 12, 2012
    Assignee: Nuliv Holding Inc.
    Inventors: Hang-Ching Lin, Wen-Liang Chang, Tsu-Chung Chang, Hsiou-Yu Ding, Tian Shung Wu
  • Patent number: 8148393
    Abstract: A zolpidem tablet having modified release is designed as a tablet-in-tablet dosage form.
    Type: Grant
    Filed: November 20, 2006
    Date of Patent: April 3, 2012
    Assignee: Synthon BV
    Inventors: Frans van Dalen, Korinde Annemarie Jansen, Farid Abedin Dorkoosh
  • Patent number: 8034371
    Abstract: The present invention provides compositions for the intranasal administration of zolpidem or a pharmaceutically acceptable salt thereof. Preferred compositions of the invention are in the form of aqueous solutions. Optionally the compositions of the invention comprise a cyclodextrin and/or chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention insomnia or the treatment of neurological disorders such as those arising from brain trauma, stroke and spinocerebellar ataxia or in the treatment of Parkinson's disease.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: October 11, 2011
    Assignee: Archimedes Development Limited
    Inventors: Jonathan David Castile, Yu-Hui Cheng, Paul George Jenkins, Alan Smith, Peter James Watts
  • Patent number: 7915307
    Abstract: Methods of improving the pharmacokinetics of doxepin in a patient.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: March 29, 2011
    Assignee: Somaxon Pharmaceuticals, Inc.
    Inventors: Cara Baron Casseday, Elizabeth Ludington, Michael Skinner, Susan Dubé, Roberta L. Rogowski, Philip Jochelson, Robert Mansbach
  • Patent number: 7914826
    Abstract: Supplemental compositions, and methods for administering same to a user, are provided for promoting a restful night's sleep by speedily inducing a person to fall asleep and to maintain sleep, as well as alleviating minor aches and pains so as to further improve the quality of a person sleep. The supplemental composition may include at least an extract of Valerian Root, an extract of Willow Bark and Melatonin or a derivative thereof. The supplemental composition may be provided for consumption at least one time daily, e.g., prior to sleep.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: March 29, 2011
    Assignee: Iomedix Sleep International SRL
    Inventors: Marvin A. Heuer, Shan Chaudhuri, Kenneth Clement
  • Patent number: 7906154
    Abstract: Supplemental compositions, and methods for administering same to a user, are provided for promoting a restful night's sleep by speedily inducing a person to fall asleep and to maintain sleep, as well as alleviating minor aches and pains so as to further improve the quality of a person sleep. The supplemental composition may include at least an extract of Valerian Root, an extract of Willow Bark and Melatonin or a derivative thereof. The supplemental composition may be provided for consumption at least one time daily, e.g., prior to sleep.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: March 15, 2011
    Inventors: Marvin A. Heuer, Shan Chaudhuri, Kenneth Clement
  • Patent number: 7674482
    Abstract: The methods and compositions for potentiating pharmaceuticals with amino acid based medical foods provides improved cognitive function; induced and maintained sleep; reduced pain, inflammation, blood pressure, anxiety, asthma, duration of viral infection, insulin resistance, and appetite; and treated depression. The amino acid based medical foods, co-packed with at least one selected pharmaceutical, potentiate the pharmaceutical by enhancing the production of neurotransmitters through the oral administration of neurotransmitter precursors, along with natural plant and animal substances that stimulate uptake of the neurotransmitter precursors, cause release of neurotransmitters, cause disinhibition of the neuronal brake, and activate adenylate cyclase in order to avoid tachyphylaxis and prevent pharmacologic tolerance.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: March 9, 2010
    Assignee: Targeted Medical Pharma Inc.
    Inventors: William E. Shell, Elizabeth Charuvastra
  • Patent number: 7662862
    Abstract: The invention relates to compounds having pharmacological activity towards the 5-HT7 receptor, and more particularly to some 2,2a,4,5-tetrahydro-1H-3-aza-acenaphthylen substituted sulfonamide compounds, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which 5-HT is involved, such as CNS disorders.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: February 16, 2010
    Assignee: Laboratorios Del Dr. Esteve, S.A.
    Inventors: Antoni Torrens Jover, Susana Yenes Mínguez, Josep Mas Prió, Luz Romero Alonso, Alberto Dordal Zueras, Helmut Henrich Buschmann
  • Patent number: 7655681
    Abstract: A method of treating or preventing Obstructive Sleep Apnea (OSA) comprises the administration of a pharmacologically effective amount of zonisamide to a patient in need thereof, with the proviso that OSA caused by external mechanical obstruction of the airways, such as by mucus, is excluded. Also disclosed is the use of zonisamide for the manufacture of a medicament useful in the treatment; a protective patch comprising zonisamide and a pharmaceutically acceptable carrier for transdermal or transmucosal administration to a person suffering from OSA; and the use of zonisamide for the manufacture of a diagnostic device, kit or composition for the diagnosis of sleep disordered breathing.
    Type: Grant
    Filed: February 15, 2005
    Date of Patent: February 2, 2010
    Inventors: Ludger Grote, Kaj Stenlof, Jan Hedner
  • Patent number: 7632517
    Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem, and optional flavoring agent; formulation II: aqueous polar solvent, zolpidem, optionally flavoring agent, and propellant; formulation III: non-polar solvent, zolpidem, and optional flavoring agent; formulation IV: non-polar solvent, zolpidem, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, zolpidem, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, zolpidem, optional flavoring agent, and propellant.
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: December 15, 2009
    Assignee: Novadel Pharma Inc.
    Inventors: Harry A. Dugger, III, Mohammed Abd El-Shafy
  • Patent number: 7351826
    Abstract: The invention provides compounds of Formula (I) that bind to GABAA receptors. In the above formula, variables are defined herein. Such compounds may be used to modulate ligand binding to GABAA receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals, and livestock animals. Compounds provided herein may be administered alone or in combination with one or more other CNS agents to potentiate the effects of the other CNS agent(s). Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting GABAA receptors (e.g.
    Type: Grant
    Filed: February 16, 2004
    Date of Patent: April 1, 2008
    Assignee: Neurogen Corporation
    Inventors: Linghong Xie, Bingsong Han, Yuelian Xu
  • Patent number: 7265155
    Abstract: Preparations and extracts of valerian, as well as isovaleramide, isovaleric acid, and certain structurally related compounds, exhibit clinically significant pharmacological properties that implicate a treatment for a variety of pathological conditions, including spasticity and convulsions, which are ameliorated by effecting a modulation of CNS activity. The compositions in question generally are non-cytotoxic and do not elicit weakness or sedative activity at doses that are effective for the symptomatic treatment of such pathological conditions.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: September 4, 2007
    Assignee: NBS Pharmaceuticals, Inc.
    Inventors: Linda D. Artman, Manuel Balandrin, Robert L. Smith
  • Patent number: 6998112
    Abstract: A toothpaste composition for inducing sleep while simultaneously promoting intraoral cleanliness, which includes toothpaste base ingredients and at least one sleep-inducing natural herb or hormone. The sleep-inducing natural herbs and hormone are selected from the group consisting of Chamomile, Lemon Balm, Passion Flower, and Valerian, and the hormone Melatonin. The sleep-inducing natural herbs are in a range of 0.25% to 18% by weight of the composition.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: February 14, 2006
    Inventor: Arthur Zuckerman
  • Patent number: 6890569
    Abstract: A restorative tea system and method of brewing a tea of one part White Willow bark, one part German Chamomile, one part Parsley, one part Nettles leaf, and one part primula veris.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: May 10, 2005
    Inventor: Ann M. Tanke
  • Patent number: 6716415
    Abstract: The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of a sedative-hypnotic. In a method aspect of the present invention, a sedative-hypnotic is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of a sedative-hypnotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: April 6, 2004
    Assignee: Alexza Molecular Delivery Corporation
    Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
  • Patent number: 6703412
    Abstract: A method of treating sleeplessness in a human comprising administering to said human suffering from said sleeplessness an effective sleep-inducing amount of not greater than about 5 mg of melatonin or a pharmaceutically acceptable salt thereof, said administration being at a point in time after said human attempts to go to sleep until no less than one hour prior to said patient's desired awakening time.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: March 9, 2004
    Inventor: Holly A. Rosenthal
  • Patent number: 6656473
    Abstract: Compositions are described comprising at least partially defatted meal from a plant source containing protein-bound tryptophan, preferably squash seeds, and, optionally, a carbohydrate source provided in an amount capable of facilitating transport of in vivo generated tryptophan across the blood brain barrier. Also described are dietary supplements, foods and beverages comprising the composition of the invention to induce sleep or provide tryptophan supplementation to individuals in need thereof.
    Type: Grant
    Filed: July 11, 2001
    Date of Patent: December 2, 2003
    Inventors: Susan P. Hudson, Craig J. Hudson
  • Patent number: 6586478
    Abstract: Methods and compositions for improving sleep in individuals with sleep disorders or other conditions which interfere with normal sleep via administration of a NO-mimetic are provided.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: July 1, 2003
    Assignee: Cellegy Canada
    Inventors: C. Bruce Ackman, Michael A. Adams, Jeremy P. W. Heaton, Jodan D. Ratz
  • Patent number: 6485746
    Abstract: Controlled-release formulations providing a “pulsed” plasma profile of a sedative-hypnotic compound having a particularly short half-life are provided. The formulation contains a sedative-hypnotic compound or precursor thereof that is metabolized to generate a sedative-hypnotic compound in vivo, wherein the compound has a mean plasma half life ranging from 0.1 to 2 hours; and at least one release retardant such that, following administration of the formulation to a patient, the patient has specified pulsed plasma profile for the sedative-hypnotic compound as disclosed herein. In a preferred embodiment, the sedative-hypnotic compound is NBI-34060.
    Type: Grant
    Filed: August 28, 2000
    Date of Patent: November 26, 2002
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: D. Bruce Campbell, W. Jay Thiele
  • Patent number: 6462089
    Abstract: The present invention relates to the use of modafinil and isomers thereof for correcting psychosocial life disturbances due to vigilance disorders observed during the evolution of myopathies.
    Type: Grant
    Filed: June 29, 2000
    Date of Patent: October 8, 2002
    Inventors: Fabrice Battaglia, Jean Krieger, Christophe Petiau, Christophe Vial, Helene Bastuji, Serge Lubin
  • Patent number: 6417399
    Abstract: The present invention generally relates to the individual stereoisomers of the drug valnoctamide (a mixture of four stereoisomer kinds, VCD-valmethamide or 2-ethyl-3-methyl pentanamide) useful in treatment of neurological and psychotic disorders such as different kinds of epilepsy and affective disorders, and useful as tranquilizers and to treat pain, and to pharmaceutical compositions containing, as an active ingredient, these stereoisomers. The present invention further relates to a method for stereoselective separation and quantification of the four stereoisomers from a racemic mixture of VCD or plasma of patients treated with the racemic drug. The present invention further relates to a unique method for the synthesis of the individual stereoisomers.
    Type: Grant
    Filed: July 13, 1999
    Date of Patent: July 9, 2002
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Meir Bialer, Boris Yagen, Ofer Spiegelstein, Michael Roeder, Volker Schurig
  • Patent number: 6395786
    Abstract: A sleep-inducing preparation which comprises as an effective ingredient a prostaglandin derivative represented by the formula: wherein X is a halogen atom, Y is a group represented by (CH2)m, a cis-vinylene group or a phenylene group, Z is an ethylene group, a trans-vinylene group, OCH2 or S(O)nCH2, R1 is a C3-10 cycloalkyl group, a C3-10 cycloalkyl group substituted with C1-4 alkyl group(s), a C4-13 cycloalkylalkyl group, a C5-10 alkyl group, a C5-10 alkenyl group, a C5-10 alkynyl group or a bridged cyclic hydrocarbon group, R2 is a hydrogen atom, a C1-10 alkyl group or a C3-10 cycloalkyl group, m is an integer of 1 to 3, and n is 0, 1 or 2, a pharmaceutically acceptable salt thereof or a hydrate thereof.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: May 28, 2002
    Assignees: Taisho Pharmaceutical Co., Ltd.
    Inventors: Fumie Sato, Tohru Tanami, Kazuya Kameo, Kenji Yamada, Shigeru Okuyama, Naoya Ono
  • Patent number: 6391309
    Abstract: A composition is prepared by extracting phytochemicals from plant matter to form a dietary supplement for treatment of female symptoms. This composition is enriched preferably with two or more fractions of plant matter, namely: isoflavones, lignans, saponins, sapogenins, catechins and phenolic acids. Soy is the preferred source of these chemicals; however, other plants may also be used, such as wheat, psyllium, rice, oats, red clover, kudzu, alfalfa, flax, and cocoa. The isoflavone may be any in a group including malonyl, acetyl, glucoside, and aglycone. The composition is in a concentrated form to be delivered in an easy to consume dosage, such as a pill, tablet, liquid, capsule, or a food supplement including health bars. Most commonly, these female symptoms are hot flashes, osteoporosis, sleep disorders, menopausal symptoms, vaginal dryness, premenstrual syndrome, or other problems relating to a reduction of sex hormones and to menstruation.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: May 21, 2002
    Assignee: Archer Daniesl Midland Company
    Inventors: Mark Empie, Eric Gugger
  • Patent number: 6365631
    Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl, including individual enantiomers or racemates thereof, (for example N,N-dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine hydrochloride optionally in the form of its monohydrate) is used for treating sleeping disorders including sleep apnoea and snoring.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: April 2, 2002
    Assignee: Knoll Pharmaceutical Company
    Inventors: Sharon C. Cheetham, David J. Heal, Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein, Anton Safer
  • Patent number: 6358941
    Abstract: The present invention relates to the use of pharmaceutically acceptable cholinesterase inhibitors for the preparation of a pharmaceutical composition for the treatment or prophylaxis of arthritic disorders, including osteoarthritis, rheumatoid arthritis and other rheumatoid diseases such as Juvenile Arthritis, Systemic Lupus Erythematosis, Sjogren's Syndrome, Progressive Systemic Sclerosis, Polymyositis, Dermatomyositis, Ankylosing Spondilitis, Reiter's Syndrome, Psoriatic Arthritis, Relapsing Polychondritis, Relapsing Panniculitis, Crohn's Disease, Ulcerative Colitis, Heredity Complement Deficiencies, Collagen Vascular Diseases, Felty's Syndrome, rheumatological manifestations associated with bacterial and viral endocarditis or myocarditis and other rheumatological manifestations such as anaemia of chronic disorders. The invention also relates to a novel method of treatment or prophylaxis of such diseases and manifestations.
    Type: Grant
    Filed: May 3, 1999
    Date of Patent: March 19, 2002
    Inventors: Ernir Snorrason, James Murray
  • Publication number: 20010051152
    Abstract: Non-pathogenic lactic acid bacteria have cell walls which are susceptible to digestion by muramidase-type enzymes, which produce fragments referred to as muramylpeptides. The ingestion of muramylpeptides, either directly, or by digestion of non-pathogenic lactic acid bacteria, promote sleep and improves the quality of sleep. In particular, non-rapid eye movement sleep phase is enhanced. The muramylpeptide digestion-products of non-pathogenic lactic acid bacteria promote monocyte production of superoxide anion and the cytokines of IL-1&bgr; and TNF&agr;.
    Type: Application
    Filed: December 20, 1999
    Publication date: December 13, 2001
    Inventors: JAMES M. KRUEGER, MICHAEL J. PABST, CHANTAL CAYUELA, MARIE-CHRISTINE DEGIVRY, DONNA HARTLEY
  • Patent number: 6277864
    Abstract: A method of treating a patient for a Sleep Disorder comprising administering an effective amount of R-(+)-&agr;-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof to a patient in need of such treatment.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: August 21, 2001
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Cesare Mondadori, Stephen M. Sorensen, Janice M. Hitchcock
  • Patent number: 6218429
    Abstract: A compound of the formula: wherein R1 is an optionally substituted hydrocarbon, amino or heterocyclic group; R2 is H or an optionally substituted hydrocarbon group; R3 is H or an optionally substituted hydrocarbon or heterocyclic group; X is CHR4, NR4, O or S in which R4 is H or an optionally substituted hydrocarbon group; Y is C, CH or N; ring A is optionally substituted 5- to 7-membered ring; ring B is an optionally substituted benzene ring; and m is 1 to 4, or a salt thereof, a process for producing it, an intermediate for the production and a pharmaceutical composition comprising it are provided.
    Type: Grant
    Filed: May 10, 1999
    Date of Patent: April 17, 2001
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Shigenori Ohkawa, Osamu Uchikawa, Kohji Fukatsu, Masaomi Miyamoto
  • Patent number: 6211229
    Abstract: The invention is directed to a method for the treatment of a patient suffering from transient or short term insomnia. The claimed method comprises the administration of a compound selected from the group consisting of the pharmaceutically acceptable forms of doxepin, amitriptyline, trimipramine, trazodone and mixtures thereof in dosages ranging from about 0.5 to about 20.0 milligrams.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: April 3, 2001
    Inventor: Neil B. Kavey
  • Patent number: 6114326
    Abstract: The present invention provides for the use of cabergoline and other agents for the treatment of restless legs syndrome (RLS).
    Type: Grant
    Filed: March 24, 1999
    Date of Patent: September 5, 2000
    Assignee: Pharmacia & Upjohn Company
    Inventor: Peter Schueler
  • Patent number: 6103766
    Abstract: Compounds of Formula I and their pharmaceutically acceptable salts having selective dopamine D3 receptor activity suitable for treating central nervous system disorders. Formula I: ##STR1## R.sub.1 is independently H or a C.sub.1 -C.sub.8 alkyl including isomeric forms thereof;R.sub.2 is H, C.sub.1 -C.sub.3 alkyl, a halogen, OCH.sub.3 , OCF.sub.3, CF.sub.3, CN, SCH.sub.3 or NHCOCH.sub.3 ; andR.sub.3 is H, C.sub.1 -C.sub.3 alkyl, a halogen, OCH.sub.3 , OCF.sub.3, CF.sub.3, CN, SCH.sub.3 or NHCOCH.sub.3.
    Type: Grant
    Filed: May 7, 1999
    Date of Patent: August 15, 2000
    Assignee: Pharmacia & Upjohn Company
    Inventors: Arthur Glenn Romero, Jeffrey A. Leiby
  • Patent number: 6090854
    Abstract: There is provided novel aryloxyanilides and related compounds of the formula ##STR1## wherein R.sup.1 is --OR, --CO.sub.2 R, or halogen with R being C.sub.1-4 alkyl;R.sup.2 is R, cyclopropyl, C.sub.2-4 alkenyl or --CH.sub.2 OR; andX is O, S, CH.sub.2, NR, SO, SO.sub.2 or COwhich are melatonergic agents and are useful in the treatment of circadian rhythm-related disorders and other conditions affected by melatonin activity.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: July 18, 2000
    Assignee: Bristol-Meyers Company
    Inventor: James R. Epperson
  • Patent number: 5990162
    Abstract: A method is provided to treat a human afflicted with chronic fatigue syndrome or fibromyalgia syndrome by the administration of certain butyrate derivatives.
    Type: Grant
    Filed: August 29, 1997
    Date of Patent: November 23, 1999
    Assignee: Orphan Medical, Inc.
    Inventor: Martin B. Scharf
  • Patent number: 5874450
    Abstract: Intranasal dosage units for promoting sleep in a mammal are disclosed. The dosage units are in the form of an aqueous buffered solution having a pH greater than 7.0, a sleep-promoting amount of Doxylamine, and an effective amount of an anionic surfactant. The anionic surfactant amount is an amount effective to provide a peak plasma concentration of Doxylamine to be reached within 30 minutes of administering the dosage unit to the nasal mucosa of a mammal. The dosage units are particularly suitable for administration to humans.
    Type: Grant
    Filed: September 29, 1997
    Date of Patent: February 23, 1999
    Assignee: Nastech Pharmaceutical Company, Inc.
    Inventors: Charanjit R. Behl, Jorge C. DeMeireles, Harish K. Pimplaskar, Vincent D. Romeo, Anthony P. Sileno, Wei J. Xia
  • Patent number: 5840331
    Abstract: Methods for reestablishing normal nocturnal growth hormone and prolactin secretion in adults with low slow-wave (deep) sleep are provided. In particular, methods are disclosed where .gamma.-hydroxybutyrate is orally administered to subjects just prior to retiring.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 24, 1998
    Assignee: Arch Development Corporation
    Inventors: Eve Van Cauter, Martin B. Scharf
  • Patent number: 5786382
    Abstract: Use of the herb/plant Valerian, in all of its forms, whether whole or in part; powdered, chopped, ground, or "tea"; the root and that portion which grows above ground; in toys; food-products; and medications (though not limited to the preceding applications); and in such manner that the natural aroma emitted by the Valerian plant will act as a powerful new scent-attractant for canines and/or felines.
    Type: Grant
    Filed: November 3, 1995
    Date of Patent: July 28, 1998
    Inventor: Vsande Childers-Zadah
  • Patent number: 5763494
    Abstract: Isovaleramide has been found to exhibit mild anxiolytic activity at low to moderate dosage levels and mildly sedative at somewhat higher dosage levels. In contrast to certain other materials thought to be anxiolytic or mildly sedative, isovaleramide is non-cytotoxic and does not paradoxically stimulate the central nervous system. Isovaleramide is therefore useful as a mild anxiolytic and mild sedative which can be made available to the general public.
    Type: Grant
    Filed: March 29, 1996
    Date of Patent: June 9, 1998
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Manuel F. Balandrin, Bradford C. Van Wagenen
  • Patent number: 5661185
    Abstract: New melatonergic agents are phenyl alkanyl or phenyl alkyl substituted carboxamides and ureas of Formula I: ##STR1## wherein: R.sub.1 =C.sub.1-3 alkyl, allyl, C.sub.3-6 cycloalkyl substituted C.sub.1-4 alkyl;R.sub.2 =hydrogen, halogen or C.sub.1-4 alkoxy;R.sub.3 =hydrogen or C.sub.1-4 alkyl;R.sub.4 =C.sub.1-4 alkyl, C.sub.1-4 alkyl substituted amino, carboxylic acid substitutedC.sub.1-4 alkyl or C.sub.3-6 cycloalkyl, C.sub.3-6 cycloalkyl, or straight or branched chainC.sub.2-4 alkenyl;A=a linear C.sub.2-4 alkanediyl or alkenediyl chain, provided that A not be --CH.sub.2 CH.sub.2 -- when X is a bond; andX=a covalent bond or oxygen.
    Type: Grant
    Filed: December 14, 1995
    Date of Patent: August 26, 1997
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Katherine S. Takaki, George N. Karageorge, Daniel J. Keavy, Michael F. Parker, Brett T. Watson
  • Patent number: 5643897
    Abstract: A method for the treatment of chronic insomnia is disclosed which involves the administration of low dosages of a compound selected from the pharmaceutically acceptable forms of doxepin, trimipramine, amitriptyline, trazodone and mixtures hereof.
    Type: Grant
    Filed: March 25, 1996
    Date of Patent: July 1, 1997
    Inventor: Neil B. Kavey
  • Patent number: 5641801
    Abstract: Methods of inducing sleepiness and sleep in an individual by administering to that individual a single dose of melatonin sufficient to induce sleepiness and sleep in the individual.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 24, 1997
    Assignee: Massachusetts Institute of Technology
    Inventor: Richard J. Wurtman
  • Patent number: 5622704
    Abstract: Use of a medicament with a content of active substances from Rhizoma zingiberis and Ginkgo bilobae for the treatment of anxiety states.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: April 22, 1997
    Assignee: Arrowdean Limited
    Inventors: Rudiger Hacker, Claudia Mattern
  • Patent number: 5612380
    Abstract: Sleep may be induced by administration of fatty acid primary amides, including cis-9,10-octadecenoamide. Furthermore, sleep deprivation may be assayed by analyzing cerebrospinal fluid with respect to the presence of fatty acid primary amides, including cis-9,10-octadecenoamide. The presence of cis-9,10-octadecenoamide in cerebrospinal fluid is correlated with comparative sleep deprivation.
    Type: Grant
    Filed: January 5, 1995
    Date of Patent: March 18, 1997
    Assignee: The Scripps Research Institute
    Inventors: Richard A. Lerner, Dale Boger, Ben Cravatt, Gary E. Siuzdak, Steven J. Henriksen
  • Patent number: 5603935
    Abstract: A composition and method for the treatment of snoring comprising an effective amount of discorea villosa and zingiber officinale in a physiologically acceptable carrier, to be administered in the form of nasal drops or spray in the nasal passages of a subject prior to sleep.
    Type: Grant
    Filed: July 29, 1995
    Date of Patent: February 18, 1997
    Assignee: Eastern Europe, Inc.
    Inventors: Weng W. Jian, David S. Riley
  • Patent number: 5569679
    Abstract: A method of pharmaceutically managing snoring is provided by the instillation intranasally of a solution containing 1-20% methylsulfonylmethane by weight dissolved in water so as to saturate the nasal mucous membranes. Preferably, the solution has between 10%-16% by weight methysulfonylmethane. The solution may be buffered, and/or a mild analgesic may be included. The method prefers that instillation occur as close to the sleep event as possible, and it should be at least within one hour before a person retires for sleep. The solution may be introduced by spray or drop-wise, and a product packaging the solution in a suitable container is described.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: October 29, 1996
    Assignee: Russell A. Krueger Pharmaceuticals, Inc.
    Inventor: Stanley W. Jacob
  • Patent number: 5565201
    Abstract: The present invention relates to a novel composition for the treatment and inhibitation of snoring. The composition according to the present invention comprises a first component and a second component. The first component is selected from Rhizoma dioscoreae nipponicae and Zingiber officinale, and the second component comprises one of more plants selected from Zingiber officinale and the Dioscoreaceae, wherein the first component is different from the second component. The present invention further involves a preparation made by the anti-snoring composition of the present invention.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: October 15, 1996
    Inventor: Hongzhi Li
  • Patent number: 5506268
    Abstract: Isovaleramide has been found to exhibit mild anxiolytic activity at low to moderate dosage levels and mildly sedative at somewhat higher dosage levels. In contrast to certain other materials thought to be anxiolytic or mildly sedative, isovaleramide is non-cytotoxic and does not paradoxically stimulate the central nervous system. Isovaleramide is therefore useful as a mild anxiolytic and mild sedative which can be made available to the general public.
    Type: Grant
    Filed: June 11, 1993
    Date of Patent: April 9, 1996
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Manuel F. Balandrin, Bradford C. Van Wagenen